Nektar Therapeutics (NKTR) Competitors $1.00 -0.03 (-2.91%) (As of 11/20/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends NKTR vs. ADCT, MCRB, AVIR, OMER, ASMB, CPIX, PCRX, AGIO, LLY, and JNJShould you be buying Nektar Therapeutics stock or one of its competitors? The main competitors of Nektar Therapeutics include ADC Therapeutics (ADCT), Seres Therapeutics (MCRB), Atea Pharmaceuticals (AVIR), Omeros (OMER), Assembly Biosciences (ASMB), Cumberland Pharmaceuticals (CPIX), Pacira BioSciences (PCRX), Agios Pharmaceuticals (AGIO), Eli Lilly and Company (LLY), and Johnson & Johnson (JNJ). These companies are all part of the "pharmaceutical preparations" industry. Nektar Therapeutics vs. ADC Therapeutics Seres Therapeutics Atea Pharmaceuticals Omeros Assembly Biosciences Cumberland Pharmaceuticals Pacira BioSciences Agios Pharmaceuticals Eli Lilly and Company Johnson & Johnson ADC Therapeutics (NYSE:ADCT) and Nektar Therapeutics (NASDAQ:NKTR) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, dividends, media sentiment, earnings, profitability, analyst recommendations, valuation, community ranking and risk. Do institutionals and insiders hold more shares of ADCT or NKTR? 41.1% of ADC Therapeutics shares are owned by institutional investors. Comparatively, 75.9% of Nektar Therapeutics shares are owned by institutional investors. 4.1% of ADC Therapeutics shares are owned by company insiders. Comparatively, 3.7% of Nektar Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Does the media prefer ADCT or NKTR? In the previous week, Nektar Therapeutics had 5 more articles in the media than ADC Therapeutics. MarketBeat recorded 6 mentions for Nektar Therapeutics and 1 mentions for ADC Therapeutics. ADC Therapeutics' average media sentiment score of 1.91 beat Nektar Therapeutics' score of 0.00 indicating that ADC Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ADC Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Nektar Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Does the MarketBeat Community believe in ADCT or NKTR? Nektar Therapeutics received 575 more outperform votes than ADC Therapeutics when rated by MarketBeat users. Likewise, 70.71% of users gave Nektar Therapeutics an outperform vote while only 66.27% of users gave ADC Therapeutics an outperform vote. CompanyUnderperformOutperformADC TherapeuticsOutperform Votes5566.27% Underperform Votes2833.73% Nektar TherapeuticsOutperform Votes63070.71% Underperform Votes26129.29% Is ADCT or NKTR more profitable? Nektar Therapeutics has a net margin of -180.70% compared to ADC Therapeutics' net margin of -300.00%. ADC Therapeutics' return on equity of 0.00% beat Nektar Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets ADC Therapeutics-300.00% N/A -61.33% Nektar Therapeutics -180.70%-173.28%-46.31% Which has better valuation and earnings, ADCT or NKTR? ADC Therapeutics has higher earnings, but lower revenue than Nektar Therapeutics. Nektar Therapeutics is trading at a lower price-to-earnings ratio than ADC Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioADC Therapeutics$70.72M2.70-$240.05M-$2.39-0.83Nektar Therapeutics$93.14M1.98-$276.06M-$0.84-1.19 Do analysts rate ADCT or NKTR? ADC Therapeutics currently has a consensus target price of $8.25, indicating a potential upside of 317.72%. Nektar Therapeutics has a consensus target price of $3.50, indicating a potential upside of 250.00%. Given ADC Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe ADC Therapeutics is more favorable than Nektar Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ADC Therapeutics 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00Nektar Therapeutics 0 Sell rating(s) 2 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.60 Which has more risk & volatility, ADCT or NKTR? ADC Therapeutics has a beta of 1.59, suggesting that its stock price is 59% more volatile than the S&P 500. Comparatively, Nektar Therapeutics has a beta of 0.61, suggesting that its stock price is 39% less volatile than the S&P 500. SummaryADC Therapeutics beats Nektar Therapeutics on 10 of the 18 factors compared between the two stocks. Ad WealthPressThis Bull Market Indicator called NVDA at $116Every now and again we find an investment idea so incredible we can’t help but share. And today is one of those rare days… Except, today we won't be giving you insight on any one particular stock… But rather, insight on a revolutionary new stock picking indicator… In fact, within the last year, this indicator has become famous for a multitude of reasons… But one of the biggest was because of the buy signal it issued on October 18th, 2022. In fact, on that very day, it said to buy NVDA at $116.37… Anyone who did would be sitting on a tremendously large return today… But even if you missed the original buy signal from October, this incredible indicator issued 11 other buy signals while Nvidia made its epic run…All you have to do is follow this link here Get Nektar Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for NKTR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NKTR vs. The Competition Export to ExcelMetricNektar TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$184.46M$6.41B$5.01B$8.81BDividend YieldN/A8.11%5.16%4.06%P/E Ratio-1.1910.57134.3717.77Price / Sales1.98243.641,158.6875.18Price / CashN/A22.1633.5332.53Price / Book1.455.474.674.68Net Income-$276.06M$153.61M$119.07M$226.08M7 Day Performance-14.53%-2.00%-1.83%-1.04%1 Month Performance-28.06%-7.47%-3.62%1.04%1 Year Performance112.77%31.80%31.63%26.28% Nektar Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NKTRNektar Therapeutics3.9366 of 5 stars$1.00-2.9%$3.50+250.0%+92.3%$184.46M$93.14M-1.19220Gap UpADCTADC Therapeutics2.8856 of 5 stars$1.98-3.9%$8.25+317.7%+177.9%$190.96M$70.72M-0.83310Positive NewsMCRBSeres Therapeutics3.8903 of 5 stars$0.81+19.0%$5.08+524.6%-16.1%$117.54M$126.32M0.00233Analyst UpgradeHigh Trading VolumeAVIRAtea Pharmaceuticals2.7567 of 5 stars$3.16+0.6%$6.88+117.7%+5.0%$266.90M$351.37M-1.5370OMEROmeros3.6817 of 5 stars$6.03flat$9.00+49.3%+244.6%$349.44MN/A0.00198Analyst UpgradeASMBAssembly Biosciences4.1342 of 5 stars$15.02-2.1%$35.00+133.0%+86.5%$97.50M$7.16M0.00100CPIXCumberland Pharmaceuticals0.7205 of 5 stars$1.12+0.9%N/A-34.9%$15.59M$36.79M-1.4580Analyst ForecastPCRXPacira BioSciences4.1777 of 5 stars$17.03+1.8%$23.50+38.0%-38.5%$772.48M$674.98M0.00720Positive NewsAGIOAgios Pharmaceuticals3.3113 of 5 stars$54.62+0.4%$52.33-4.2%+154.0%$3.10B$32.87M4.81390LLYEli Lilly and Company4.9914 of 5 stars$753.41+3.2%$1,007.94+33.8%+26.0%$692.74B$34.12B81.4543,000Positive NewsJNJJohnson & Johnson4.9618 of 5 stars$153.10+0.1%$175.94+14.9%+2.1%$368.37B$85.16B22.16131,900Positive News Related Companies and Tools Related Companies ADCT Competitors MCRB Competitors AVIR Competitors OMER Competitors ASMB Competitors CPIX Competitors PCRX Competitors AGIO Competitors LLY Competitors JNJ Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:NKTR) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored24/7 Automated Profits in CryptoThe 4th quarter of 2024 is shaping up to be one of the most explosive periods for crypto in recent memory. But...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | SponsoredBut another coin could soar even higher …Donald Trump wants to be America’s first crypto president. He was the keynote speaker at the recent Bitcoin co...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Nektar Therapeutics Please log in to your account or sign up in order to add this asset to your watchlist. Share Nektar Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
